spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  VEGFR2 

 HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 May 2019
Portage Announces Change of CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2015
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Apr 2014
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals
 HSMN NewsFeed - 22 Sep 2009
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 Jun 2007
Cyclacel Pharmaceuticals Announces Appointment of Distinguished Pharma Executive as Senior Vice President, Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2007
Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
VEGFR2
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!